Damanhour University   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Damanhour Egypt (2010)

Organization Overview

First Clinical Trial
2012
NCT01767259
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Clinical Pharmacy Lecturer | Clinical Pharmacy Specialist, Damanhour University. | Damanhour Teaching Hospital | Damanhour Teatching Hospital | Damanhour University | Damanhour University, Faculty of Pharmacy | Faculty of Nursing, Damanhour University | Faculty of pharmacy, Damanhour University | Lecturer of Analytical chemistry, Damanhour University. | Lecturer of biochemisrty, Damanhour University. | Lecturer of Clinical Pharmacy, Damanhour University. | Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt | Pharmacology & Toxicology department- faculty of pharmacy- Damanhour University. | Professor in Pharmacology, Faculty of pharmacy, Damanhour University | Professor of Biochemistry, Damanhour University. | Professor of Pharmacology, Faculty of pharmacy, Damanhour University | Rehab Werida

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Brain Injuries (Phase 4)

Brain Injuries, Traumatic (Phase 4)

Breast Neoplasms (Phase 2)

Cardiomyopathies (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Critical Illness (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Fractures, Bone (Phase 4)

Headache (Phase 4)

Heart Failure (Phase 4)

Hypertension (Phase 4)

Hypertension, Renal (Phase 4)

Inflammation (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Injury (Phase 2)

Myocardial Ischemia (Phase 4)

Post-Dural Puncture Headache (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Shock (Phase 2)

Shock, Septic (Phase 2)

Transfusion-Related Acute Lung Injury (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 44